Recent Updates
Recently added Catalysts
ADMA Negative Sentiment Score: 20/100

ADMA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ADMA Biologics, Inc. and Encourages Investors to Contact the Firm

Key Takeaway: A class action lawsuit has been filed against ADMA Biologics, Inc. in the United States District Court for the District of New Jersey. The lawsuit claims that ADMA made false statements and failed to disclose material unfavorable facts about its business. Allegations include engaging in related party transactions and using channel stuffing to misrepresent revenue figures. Following a negative report by Culper Research, ADMA's stock saw a significant decline in value.

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action lawsuit alleges misleading statements from ADMA.
  • Recent allegations of channel stuffing to inflate revenues.
  • ADMA's stock price fell by over 16% following negative report.
  • Concerns over inadequate internal controls at ADMA.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In ADMA To Contact Him Directly To Discuss Their Options
If you purchased or acquired ADMA Biologics securities between August 9, 2024 and March 25, 2026 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired ADMA Biologics securities between August 9, 2024 and March 25, 2026, both dates inclusive (the “Class Period”). Investors have until August 10, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts regarding ADMA’s business, operations, and prospects, including allegations that: (1) ADMA engaged in an undisclosed related party transaction; (2) ADMA used channel stuffing to create an appearance of revenue; and (3) ADMA lacked adequate internal controls.
On March 24, 2026, Culper Research published a short report on ADMA, alleging that "ADMA's reported growth is a fiction driven more than entirely by a de facto channel stuffing scheme and an undisclosed related party distributor" and "estimat[ing] that, absent channel stuffing, ADMA revenues declined 3% in 2025 vs. +20% reported."
Following publication of the Culper report, ADMA's stock price fell $2.26 per share, or 16.63%, to close at $11.33 per share on March 24, 2026.
If you purchased or otherwise acquired ADMA shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

Who should contact Bragar Eagel & Squire about ADMA losses?

Investors who bought ADMA securities between August 9, 2024, and March 25, 2026.

What is the deadline to apply as lead plaintiff?

Investors have until August 10, 2026, to apply for lead plaintiff status.

What allegations are made against ADMA Biologics?

Allegations include undisclosed transactions, channel stuffing, and weak internal controls.

How much did ADMA's stock price fall on March 24, 2026?

ADMA's stock price fell by $2.26, or 16.63%, closing at $11.33 per share.

How can investors learn more about Brandon Walker's services?

Investors can contact Brandon Walker at (212) 355-4648 or via email.

Last updated: Jun 11, 2026